A targeted approach to reducing lung cancer mortality

Journal of Clinical Oncology

Volumn 23, Issue 14, 2005, Pages 3173-3174

  Shepherd, Frances A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; EDITORIAL; HIGH RISK POPULATION; HUMAN; INCIDENCE; LUNG CANCER; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TOBACCO; LUNG TUMOR; MASS SCREENING; METHODOLOGY; MORTALITY; NOTE; PRIMARY PREVENTION;

HUMANS; LUNG NEOPLASMS; MASS SCREENING; MORTALITY; PRIMARY PREVENTION;

EID: 19844376521     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.001     Document Type: Editorial

References (3)

1. Mulshine JL: New developments in lung cancer screening. J Clin Oncol 23: 3198-3202, 2005
2. Winter T, Livingston R, Johnson D, et al: Adjuvant chemotherapy improves survival post resection of non-small cell lung cancer. N Engl J Med: in press
3. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22: 6215, 2004 (suppl; abstr 7019)